PATENT CLAIM ANALYSIS

Application Number: 16181088
Application Type: Utility
Filing Date: 2018-11
Publication Date: 2019-06
Patent Classification: ["424", "136100"]

Abstract:
The present invention is in the fields of biochemistry, molecular biology, and Alzheimer's disease diagnosis, prevention, and treatment. Provided herein are humanized antibodies against human tau that are capable of discriminating between normal (healthy) and pathological (disease-associated) tau.

Claim (Index 191):
The composition of  claim 180 , wherein the second therapeutic agent is selected from one of more of an acetylcholinesterase inhibitor, donepezil, rivastigmine, galantamine, tacrine, nutritive supplements, N-Methyl-D-aspartate (NMDA) receptor antagonists, memantine, an inhibitor of DNA repair, pirenzepine or a metabolite thereof, a transition metal chelator, a growth factor, a hormone, a non-steroidal anti-inflammatory drug (NSAID), an antioxidant, a lipid lowering agent, a selective phosphodiesterase inhibitor, an inhibitor of tau aggregation, an inhibitor of a protein kinase, an anti-mitochondrial dysfunction drug, a neurotrophin, an inhibitors of a heat shock protein, an inhibitor of Lipoprotein-associated phospholipase A 2 , an anti-apoptotic compound, a metal chelator, an inhibitor of DNA repair, 3-amino-1-propanesulfonic acid (3APS), 1,3-propanedisulfonate (1,3PDS), a secretase activator, a beta-secretase inhibitor, a gamma-secretase inhibitor, a beta-amyloid peptide, an anti-beta-amyloid antibody, a neurotransmitter, a beta-sheet breaker, an anti-inflammatory molecule, a BACE inhibitor, a muscarinic antagonist, a cholinesterase inhibitor, a gamma secretase inhibitor, a gamma secretase modulator, an HMG-CoA reductase inhibitor, a non-steroidal anti-inflammatory agent, an NMDA receptor antagonist, an anti-amyloid antibody, vitamin E, a nicotinic acetylcholine receptor agonist, a CB1 receptor inverse agonist, a CB1 receptor antagonist, an antibiotic, a histamine H3 antagonist, an AMPA agonist, a PDE4 inhibitor, a GABAA inverse agonist, an inhibitor of amyloid aggregation, a glycogen synthase kinase beta inhibitor, a promoter of alpha secretase activity, a PDE-10 inhibitor, a cholesterol absorption inhibitor, and any pharmaceutically acceptable salts thereof.

Metadata:
- Claim Count in Document: 79.0
- Percentile: 98.0
- Lexical Diversity: 1.28947
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15528333', '15342629', '15599685', '15906773', '15207836']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7702234108873023
- 35 USC 102 Novelty (BERT): 0.6424900157956186
- Combined Prediction Score: 0.7574500713781339
- Mean Citation Score: 506.236552
- Max Citation Score: 786.5726
- Similarity Product: 545.0878408039331

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test